| Variables |
| Before PSM |
|
| After PSM |
|
| F0~4 (n = 166) | F5~6 (n = 1370) | P value | F0~4 (n = 164) | F5~6 (n = 164) | P value | |
| Age at diagnosis (mean ± SD) | 57.70 ± 7.28 | 57.89 ± 6.87 | 0.745 | 57.66 ± 7.31 | 59.44 ± 6.20 | 0.024 |
| Sex, n |
|
| 0.451 |
|
| 1.000 |
| Male | 134 (80.7%) | 1,071 (78.2%) |
| 132 (80.5%) | 133 (81.1%) |
|
| Female | 32 (19.3%) | 299 (21.8%) |
| 32 (19.5%) | 31 (18.9%) |
|
| Race (White, Black, Other) |
|
| 0.005 |
|
| 0.349 |
| White | 112 (67.5%) | 1071 (78.6%) |
| 111 (67.7%) | 117 (71.3%) |
|
| Black | 19 (11.4%) | 111 (8.1%) |
| 19 (11.6%) | 17 (10.4%) |
|
| Other | 35 (21.1%) | 180 (13.2%) |
| 34 (20.7%) | 30 (18.3%) |
|
| AJCC T, 7th ed., n |
|
| 0.360 |
|
| 0.421 |
| T1~T2 | 74 (44.6%) | 691 (50.4%) |
| 72 (43.9%) | 83 (50.6%) |
|
| T3~T4 | 4 (2.4%) | 31 (2.3%) |
| 4 (2.4%) | 4 (2.4%) |
|
| Unclear | 88 (53.0%) | 648 (47.3%) |
| 88 (53.7%) | 77 (47.0%) |
|
| AJCC N, 7th ed., n |
|
| 0.065 |
|
| 0.101 |
| N0 | 73 (44.0%) | 718 (52.4%) |
| 73 (44.5%) | 84 (51.2%) |
|
| N1 | 1 (0.6%) | 4 (0.3%) |
| 1 (0.6%) | 1 (0.6%) |
|
| Unclear | 92 (55.4%) | 648 (47.3%) |
| 90 (54.9%) | 79 (48.2%) |
|
| AJCC M, 7th ed., n |
|
| 0.268 |
|
| 0.135 |
| M0 | 78 (47.0%) | 718 (52.4%) |
| 76 (46.3%) | 87 (53.0%) |
|
| M1 | 0 (0.0%) | 6 (0.4%) |
| 0 (0.0%) | 0 (0.0%) |
|
| Unclear | 88 (53.0%) | 646 (47.2%) |
| 88 (53.7%) | 77 (47.0%) |
|
| AFP, n |
|
| 0.163 |
|
| 0.057 |
| Positive/elevated | 90 (54.2%) | 668 (48.8%) |
| 89 (54.3%) | 78 (47.6%) |
|
| Negative | 44 (26.5%) | 464 (33.9%) |
| 44 (26.8%) | 61 (37.2%) |
|
| Unclear | 32 (19.3%) | 238 (17.4%) |
| 31 (18.9%) | 25 (15.2%) |
|
| Tumor size, n |
|
| 0.366 |
|
| 1.000 |
| ≤1 cm | 154 (92.8%) | 1267 (92.5%) |
| 152 (92.7%) | 152 (92.7%) |
|
| >1 cm | 1 (0.6%) | 2 (0.1%) |
| 1 (0.6%) | 1 (0.6%) |
|
| Unclear | 11 (6.6%) | 101 (7.4%) |
| 11 (6.7%) | 11 (6.7%) |
|
| Grade, n |
|
| 0.264 |
|
| 0.377 |
| Well differentiated; Grade I | 51 (30.7%) | 332 (24.2%) |
| 50 (30.5%) | 42 (25.6%) |
|
| Moderately differentiated; Grade II | 52 (31.3%) | 526 (38.4%) |
| 51 (31.1%) | 69 (42.1%) |
|
| Poorly differentiated; Grade III | 15 (9.0%) | 100 (7.3%) |
| 15 (9.1%) | 14 (8.5%) |
|
| Undifferentiated; anaplastic; Grade IV | 1 (0.6%) | 6 (0.4%) |
| 1 (0.6%) | 1 (0.6%) |
|
| Unknown | 47 (28.3%) | 406 (29.6%) |
| 47 (28.7%) | 38 (23.2%) |
|
| Lymph involvement, n |
|
| 0.775 |
|
| 0.808 |
| No | 151 (91.0%) | 1266 (92.4%) |
| 151 (92.1%) | 150 (91.5%) |
|
| Yes | 1 (0.6%) | 9 (0.7%) |
| 1 (0.6%) | 1 (0.6%) |
|
| Unclear | 14 (8.4%) | 95 (6.9%) |
| 12 (7.3%) | 13 (7.9%) |
|
| Distant metastasis, n |
|
| 0.614 |
|
| / |
| No | 155 (93.4%) | 1271 (92.8%) |
| 154 (93.9%) | 152 (92.7%) |
|
| Yes | 0 (0.0%) | 8 (0.6%) |
| 0 (0.0%) | 1 (0.6%) |
|
| Unclear | 11 (6.6%) | 91 (6.6%) |
| 10 (6.1%) | 11 (6.7%) |
|